AEON Biopharma, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
AEON NYSE American 2836 www.aeonbiopharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for AEON Biopharma, Inc.

AEON Announces Positive Pilot Forced Degradation Results Supporting Analytical Comparability of ABP-450 to BOTOX® - Sep 9th, 2026 6:00 am
AEON Biopharma to Participate in Lake Street Capital Markets’ 10th Annual Best Ideas Growth (BIG10) Conference - Aug 31st, 2026 6:00 am
AEON Biopharma Designates Former FDA Neuroscience Leader Paul Lee, M.D., Ph.D. as Acting Chief Regulatory Officer - Aug 24th, 2026 6:00 am
AEON Reports Expanded Structural Data Supporting Molecular Similarity of ABP-450 to BOTOX® - Aug 19th, 2026 6:00 am
AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Aug 12th, 2026 2:15 pm
AEON Biopharma Regains Compliance with NYSE American Continued Listing Standards - Aug 3rd, 2026 2:15 pm
Humana upgraded, Las Vegas Sands downgraded: Wall Street's top analyst calls - Jul 30th, 2026 7:38 am
AEON Biopharma Announces Pricing of Upsized $13.75 Million Public Offering with Accompanying Milestone Warrants Providing Potential for Additional Future Funding - Jul 14th, 2026 6:00 am
AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society - Jun 4th, 2026 5:00 am
Cervical Dystonia Market to Witness Robust Growth During the Forecast Period (2026-2036) Driven by the Expanding Therapeutic Options | DelveInsight - Jun 2nd, 2026 8:01 am
Why You Might Be Interested In Aeon Co. (M) Bhd. (KLSE:AEON) For Its Upcoming Dividend - May 24th, 2026 6:02 pm
AEON Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate Update - May 14th, 2026 2:05 pm
AEON Biopharma Sets Annual Shareholder Meeting - Apr 24th, 2026 2:05 pm
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 - Apr 3rd, 2026 2:10 pm
AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards - Apr 3rd, 2026 2:05 pm
AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program - Mar 30th, 2026 2:05 pm
Aeon Biopharma announces FDA feedback after Type 2a meeting - Mar 26th, 2026 6:17 am
AEON Biopharma Announces FDA Feedback Following BPD Type 2a Meeting for the ABP-450 Biosimilar Program - Mar 25th, 2026 6:00 am
AEON Biopharma Appoints John Bencich as Chief Financial Officer - Mar 9th, 2026 2:05 pm
AEON Biopharma Abstract Accepted for Presentation at 2026 American Academy of Neurology (AAN) Annual Meeting - Mar 5th, 2026 2:05 pm